Enhancing HSV-1 as an Antitumor Gene Therapy Vector

增强 HSV-1 作为抗肿瘤基因治疗载体

• 批准号: 6884553
• 负责人: AMISH C SHAH
• 金额: $ 2.97万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-27 至 2007-09-26
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6884553
• 关键词: biotechnology; gene therapy; glioma; herpes simplex virus 1; immune response; immunomodulators; interleukin 12; laboratory mouse; mutant; neoplasm /cancer immunotherapy; neurotoxicology; nonhuman therapy evaluation; predoctoral investigator; recombinant DNA; transfection /expression vector; virus replication

DESCRIPTION (provided by applicant): Malignant gliomas have defied advances in traditional therapies and have engendered intensive exploration into the study of novel treatment modalities, including the use of viral vectors for gene therapy. Mutation of the gamma134.5 gene in HSV-1 has made it a promising therapeutic candidate as a conditionally replicating viral vector whose successful replication and oncolysis is limited to tumor cells. The proposed studies will improve the potential of HSV as a gene therapy agent by both enhancing its intrinsic anti-tumor capabilities and optimizing its extrinsic arsenal of recombinant immunostimulatory therapeutic genes. The first approach will be to enhance its "intrinsic" ability to function within the tumor environment. Serially passaging gamma134.5-deficient HSVs through human malignant gliomas (D54 and U87) grown in the flanks of SCID mice will allow in vivo selective pressures to produce mutants possessing enhanced anti-glioma activity. The second "extrinsic" approach will augment the cytoreductive and curative ability of the virus by optimizing its ability to promote tumor-targeted immune responses. Construction of an HSV-1 vector expressing IL-18 is expected to elicit increased immune cell infiltrates targeting tumor cells for destruction. Furthermore, using a combination of IL- 18-expressing HSV with M002 (IL-12-expressing HSV), or an HSV expressing both IL-12 & IL-18, should lead to greater anti-tumor effects due to the proven synergy between IL-12 and IL-18. Finally, we anticipate that unifaction of oncolytics gamma134.5(-) HSV-1 vectors selected through serial passaging with different immunostimulatory genes will deliver a therapeutic "double hit" against these recalcitrant and nearly universally fatal malignant gliomas.

描述（由申请人提供）：恶性胶质瘤已经挑战了传统治疗方法的进展，并引发了对新治疗方式研究的深入探索，包括使用病毒载体进行基因治疗。HSV-1中γ - 134.5基因的突变使其成为一种有前途的治疗候选病毒载体，其成功的复制和肿瘤分解仅限于肿瘤细胞。所提出的研究将通过增强其内在抗肿瘤能力和优化其外部重组免疫刺激治疗基因库来提高HSV作为基因治疗剂的潜力。第一种方法将是增强其在肿瘤环境中发挥作用的“内在”能力。通过在SCID小鼠侧翼生长的人类恶性胶质瘤（D54和U87）中连续传递γ - 134.5缺陷hsv，将允许在体内选择压力下产生具有增强抗胶质瘤活性的突变体。第二种“外在”方法将通过优化其促进肿瘤靶向免疫反应的能力来增强病毒的细胞减少和治疗能力。构建表达IL-18的HSV-1载体有望引发更多靶向肿瘤细胞的免疫细胞浸润。此外，将表达IL-18的HSV与M002（表达IL-12的HSV）联合使用，或同时表达IL-12和IL-18的HSV，由于IL-12和IL-18之间已证实的协同作用，应该会产生更大的抗肿瘤效果。最后，我们预计通过不同的免疫刺激基因串联传代选择的溶瘤学γ - 134.5(-) HSV-1载体的统一将提供治疗“双重打击”，以对抗这些顽固性和几乎普遍致命的恶性胶质瘤。